Drug Profile
AVE 9940
Alternative Names: AVE9940Latest Information Update: 04 Oct 2005
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Aug 2005 Discontinued - Phase-I for Rheumatoid arthritis (unspecified route)